With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion. A key reason for this activity is the ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

Posters detail large gene insertion and epigenetic editing capabilities, expanding ElevateBio’s gene editing toolbox– Additional presentations ...

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.

Intellia Therapeutics has begun a rolling FDA submission for lonvoguran ziclumeran (lonvo-z) after its phase 3 trial showed an 87% reduction in hereditary angioedema attacks versus placebo. The ...

Retrons adapted from E. coli enable genome editing in 15 diverse bacterial species, expanding recombineering tools across major microbial phyla.

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

Artificial intelligence is supercharging CRISPR genome editing, making it faster, more precise, and safer. From designing optimal guide RNAs to predicting and preventing off-target effects, AI tools ...